ECA39 is a novel distant metastasis-related biomarker in colorectal cancer
ECA39 is a novel distant metastasis-related biomarker in colorectal cancer
复制标题
DOI：
10.3748/wjg.v12.i36.5884
复制
发表时间：
2006-09-28
影响因子：
4.3
通讯作者：
Hashimoto-Tamaoki, Tomoko
中科院分区：
文献类型：
--
作者：
Yoshikawa, Reigetsu;Yanagi, Hidenori;Hashimoto-Tamaoki, Tomoko
目的：探讨多糖k （PSK）相关标志物在预测结直肠癌（CRC）远处转移及临床预后中的可能作用。方法：首先，我们利用蛋白微阵列技术分析psk相关潜在标志物在携带突变p53基因的人结直肠癌细胞系SW480中的体外表达谱。然后，我们研究了这些标志物在结直肠癌患者预后中的临床意义。结果：ECA39是c-Myc的直接靶点，被确定为受PSK抗转移作用影响的候选蛋白。免疫组化结果显示，有远处转移的肿瘤组织中ECA39的表达水平明显高于无远处转移的肿瘤组织（P < 0.00001）。ECA39阳性表达对预测远处转移具有高度可靠性（敏感性86.7%，特异性90%，阳性预测值86.7%，阴性预测值90%）。eca39阴性组的5年累积无病生存率（77.3%）显著高于eca39阳性组（25.8%）（P < 0.05）。结论：我们的研究结果表明，ECA39是晚期结直肠癌患者远处转移的主要预测因素，PSK抑制其可能代表了免疫治疗作为综合医学计划一部分的有用应用。(C) 2006 WJG出版社。版权所有。
AIM: To investigate the possible role of polysaccharide-K (PSK) -related markers in predicting distant metastasis and in the clinical outcome of colorectal cancer (CRC).METHODS: Firstly, we used protein microarrays to analyze the in vitro expression profiles of potential PSK-related markers in the human colorectal adenocarcinoma cell line SW480, which carries a mutantp53 gene. Then, we investigated the clinical implications of these markers in the prognosis of CRC patients.RESULTS: ECA39, a direct target of c-Myc, was identified as a candidate protein affected by the anti-metastatic effects of PSK. Immunohistochemistry revealed that ECA39 was expressed at significantly higher levels in tumor tissues with distant metastases compared to those without (P < 0.00001). Positive ECA39 expression was shown to be highly reliable for the prediction of distant metastases (sensitivity: 86.7%, specificity: 90%, positive predictive value: 86.7%, negative predictive value: 90%). A significantly higher cumulative 5-yr disease free survival rate was observed in the ECA39-negative patient group (77.3%) compared with the ECA39-positive patient group (25.8%) (P < 0.05).CONCLUSION: Our results suggest that ECA39 is a dominant predictive factor for distant metastasis in patients with advanced CRC and that its suppression by PSK might represent a useful application of immunotherapy as part of a program of integrated medicine. (C) 2006 The WJG Press. All rights reserved.